Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant.
about
Carbohydrates as T-cell antigens with implications in health and disease.Intranasal Vaccination With Salmonella-Derived Serodominant Secreted Effector Protein B Associated With Gas-Filled Microbubbles Partially Protects Against Gut Infection in Mice.Prophylactic Sublingual Immunization with Mycobacterium tuberculosis Subunit Vaccine Incorporating the Natural Killer T Cell Agonist Alpha-Galactosylceramide Enhances Protective Immunity to Limit Pulmonary and Extra-Pulmonary Bacterial Burden in MicLipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.
P2860
Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Enhancement of Mucosal Immunog ...... alactosylceramide as Adjuvant.
@ast
Enhancement of Mucosal Immunog ...... alactosylceramide as Adjuvant.
@en
Enhancement of Mucosal Immunog ...... alactosylceramide as Adjuvant.
@nl
type
label
Enhancement of Mucosal Immunog ...... alactosylceramide as Adjuvant.
@ast
Enhancement of Mucosal Immunog ...... alactosylceramide as Adjuvant.
@en
Enhancement of Mucosal Immunog ...... alactosylceramide as Adjuvant.
@nl
prefLabel
Enhancement of Mucosal Immunog ...... alactosylceramide as Adjuvant.
@ast
Enhancement of Mucosal Immunog ...... alactosylceramide as Adjuvant.
@en
Enhancement of Mucosal Immunog ...... alactosylceramide as Adjuvant.
@nl
P2093
P2860
P356
P1433
P1476
Enhancement of Mucosal Immunog ...... alactosylceramide as Adjuvant.
@en
P2093
Bharti Nehete
Guojun Yang
Michael A Barry
Pramod N Nehete
Shailbala Singh
P2860
P304
P356
10.3390/VACCINES2040686
P577
2014-10-01T00:00:00Z